Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma
Summary analysis demonstrates high response rates and manageable toxicity of HBI0101 CAR T-cell therapy in relapsed multiple myeloma, suggesting its clinical potential.
Key Points
Complete response rate reached 71% in patients treated with HBI0101 anti-BCMA chimeric antigen receptor T-cells.
Median progression-free survival was 14.6 months, with 93% overall response in patients with relapsed multiple myeloma.
Manufacturing success rate stood at 100%, with manageable toxicities including frequent cytokine release syndrome.
High efficacy seen in complex cases emphasizes the need for CAR T-cell therapy in challenging populations.